- Feasibility study on a TDR pooled fund for R&D to be released on 20 February 2016
- SAVE THE DATE - 26 January 2016: Implications of the TPP and RCEP on Universal Health Coverage
- Xtandi 2016 March-In Request
- Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutes
- 51 members of Congress have asked the NIH to use March-In rights to rein in high drug prices
- WHO's evaluation of the global strategy and plan of action on public health, innovation and intellectual property
- FDA approves 45 new drugs. 47 percent qualify for 50 percent Orphan Drug tax credit
- KEI's December 19, 2015 submission to the US ITC regarding the TPP
- The UK's rebates on drug sales, and introducing the budget constraint into pricing models
- SAVE THE DATE - 16 December 2015 - KEI breakout session on A WTO Agreement on the Supply of Social Goods
Contrast in privilege: US officials working to block WTO LDC drug patent waiver, and people affected by policySubmitted by James Love on 17. October 2015 - 16:57
On the left, the people in the Obama Administration trying to block a permanent waiver of WTO drug patent obligations for Least Developed Countries (as defined by the UN). On the right, some people living in least developed countries.
Ambassador Michael Forman. Head of USTR. Alma maters: Princeton, Oxford and Harvard Law. Formerly ran a hedge fund for Citibank.
On Wednesday, October 14, 2015, KEI staff and members of Public Citizen's Global Access to Medicines team demonstrated outside of the White House and USTR, urging the administration, especially USTR and Ambassador Michael Froman, to support a request for a permanent drug patent waiver for Least Developed Countries (LDCs) at the WTO.
Below are images from the protest action, also available in higher resolution here. And, yes, you can use these photos under any creative commons or wikimedia license.
In the early hours of Thursday morning, 15 October 2015, the WIPO General Assembly adopted the following decision related to the future work of the Standing Committee on Copyright and Related Rights (SCCR). There was no consensus on future work so the Assembly directed the SCCR to "continue its work" on the protection of broadcasting organizations and copyright limitations and exceptions.
Below you will find a collection of articles in the press and commentary by KEI relating to the request for LDC patent exemption on pharmaceutical products at the WTO.
Attached is a letter, dated October 14, 2015, from Senator Sherrod Brown to USTR's Ambassador Michael Froman, urging USTR to support a permanent waiver of WTO drug patent rules, for Least Developed Countries. Negotiations on this issue begin formally on October 15, 2015, during a meeting of the WTO TRIPS Council.
Among the money quotes:
Final draft, India National IPR Policy, by IP Think Tank constituted by DIPP, Ministry of Commerce and IndustrySubmitted by KEI Staff on 14. October 2015 - 5:47
This is a copy of recommendations for an Indian National IPR Policy, written by the "IP Think Tank," which was constituted by the Department of Industrial Policy & Promotion(DIPP), Ministry of Commerce and Industry, Government of India. A copy scanned from a hard copy is here.
The members of the IPR Think Tank were:
- Justice Prabha Sridevan (Retd) - Chairperson
- Mrs. Prathiba M. Singh, Senior Advocate - Member
- Mr. Narendra K. Sabharwal - Member & Convener
The World Intellectual Property Organization's (WIPO) General Assembly is currently engaged five separate informal consultations on the following topics: 1) Lisbon Union, 2) the future of the Intergovernmental Committee on Genetic Resources, Traditional Knowledge and Folklore, 3) the work program of the Standing Committee on Copyright and Related Rights (SCCR), 4) the Design Law Treaty and 5) WIPO External Offices.
WTO TRIPS Council (October 2015) to discuss LDC extension for pharmaceuticals, non-violation, review of the Paragraph 6 systemSubmitted by thiru on 12. October 2015 - 11:56
The WTO TRIPS Council meets from Thursday, 15 October 2015 to Friday, 16 October 2015. The hot topics for consideration include agenda item 13 (Request from the LDC Group for an indefinite exemption from WTO IP obligations to provide patents for pharmaceutical products, agenda item 8 (non-violation and situation complaints), agenda item 7 (Review of the Paragraph 6 system) and agenda item 14 (a discussion item co-sponsored by Australia, the European Union and the United States on "Intellectual Property and Innovation: Entrepreneurialism and New Technologies).
Members of the World Trade Organization (WTO) meet this week in Geneva (15 October 2015 - 16 October 2015) to decide if the poorest countries on earth are exempt from WTO rules for pharmaceutical patents. The WTO's TRIPS Council is expected to make a decision in respect of the request of the LDC Group's request for indefinite exemption from TRIPS obligations on pharmaceutical patents.
This is a video explaining the request by the Coalition for Affordable T-DM1 to use the Crown Use provisions in the UK patents law, in order to grant compulsory licences on the patents relating to the cancer drug T-DM1, marketed by Roche under the brand name Kadcyla. The video was produced and edited by Zack Struver for KEI, and features narration by Merith Basey from UAEM.
Press Releases and Articles about the IP Chapter of the TPP
Leaked text can be found here.
On 9 October 2015, Wikileaks released the final text of the IP chapter in the Trans-Pacific Partnership. Jamie Love provided comments via twitter.
Updated: 9 October 2015
(In the order posted)
- Wikileaks has the October 5, 2015 version of the #TPP IP Chapter. https://wikileaks.org/tpp-ip3/WikiLeaks-TPP-IP-Chapter/WikiLeaks-TPP-IP-Chapter-051015.pdf
WIPO General Assembly 2015: Statement of United States on Broadcasting Treaty and Copyright Limitations and ExceptionsSubmitted by thiru on 8. October 2015 - 23:33
On Wednesday, 7 October 2015, the United States of America delivered the following statement on agenda item 12 (Report on the Standing Committee on Copyright and Related Rights). The US expressed support for a broadcasting treaty under a signal-based approach, focused on "unauthorized simultaneous or near-simultaneous retransmission of broadcast signals to the public over any type of platform, including the Internet."
On copyright limitations and exceptions, the US expressed support for
FDA enforcement discretion to allow unregistered generic Daraprim to be imported and sold at lower pricesSubmitted by James Love on 8. October 2015 - 19:09
In 2011, the FDA told the NIH it could use enforcement discretion to permit importation and sale of unregistered drugs
In 2011, in the context of a shortage of Fabrazyme, the FDA told the NIH if they could "in theory" allow Shire to import and sell Replagal, a drug approved for sale in Europe, but not in the United States, as an unregistered biologic substitute. The remedy explored for the Fabrazyme shortage may be the best way to address a different problem, the price gouging associated with the drug Daraprim (generic name: pyrimethamine).
Statement of KEI on announcement that there is a consensus on the Trans Pacific Partnership (TPP) trade agreement
October 5, 2015, 10am, EST
These comments by James Love, KEI Director